Beijing Jishuitan Hospital

Meta-Analysis Confirms Efficacy of Traditional Chinese Medicine Si-Shen-Wan for Treating IBS-D

a day ago

• A comprehensive meta-analysis of 34 randomized controlled trials involving 2,976 participants has validated the efficacy of Si-Shen-Wan (SSW) in treating diarrhea-predominant irritable bowel syndrome. • The traditional Chinese medicine formula demonstrated significant improvements in multiple symptom scores including abdominal pain, diarrhea, abdominal distension, and loss of appetite in IBS-D patients. • Researchers from leading Chinese medical institutions employed trial sequential analysis to ensure robust findings, potentially offering a valuable alternative treatment for this common functional gastrointestinal disorder.

Pimicotinib Shows Positive Phase 3 Results for Tenosynovial Giant Cell Tumor

6 months ago

• Abbisko's pimicotinib demonstrated a statistically significant objective response rate (ORR) of 54.0% versus 3.2% for placebo in TGCT patients at Week 25. • The MANEUVER study showed clinically meaningful improvements in stiffness and pain, key patient-reported outcomes, with pimicotinib treatment. • Pimicotinib was well-tolerated, with a safety profile consistent with prior data and no evidence of cholestatic hepatotoxicity observed. • Merck has an exclusive license to commercialize pimicotinib in Greater China and an option for global commercial rights.

Pimicotinib Demonstrates Significant Efficacy in Tenosynovial Giant Cell Tumor (TGCT) Phase 3 Trial

6 months ago

• Pimicotinib achieved a 54.0% objective response rate (ORR) at 25 weeks in TGCT patients, significantly higher than the 3.2% ORR observed with placebo. • The MANEUVER trial demonstrated statistically significant improvements in secondary endpoints, including stiffness and pain reduction, with pimicotinib treatment. • Pimicotinib's safety profile in the trial was consistent with previous reports, with no signs of cholestatic hepatoxicity observed. • The FDA previously granted breakthrough therapy designation to pimicotinib for TGCT, highlighting its potential as a new treatment option.

Abbisko's Pimicotinib Shows Promise in Phase 3 Trial for Tenosynovial Giant Cell Tumor

6 months ago

• Pimicotinib, an oral drug developed by Abbisko Therapeutics, demonstrated a 54% tumor shrinkage rate in patients with tenosynovial giant cell tumor (TGCT). • The Phase 3 MANEUVER study evaluated pimicotinib against placebo in patients with TGCT who had not received prior CSF-1R inhibitor treatment. • Pimicotinib showed significant improvements in secondary endpoints like stiffness and pain and was well-tolerated among the patients. • Merck KGaA holds commercial rights to pimicotinib in mainland China, Hong Kong, Macau, and Taiwan, with plans to explore its use in other solid tumors.

Pimicotinib Demonstrates Significant Efficacy in Phase 3 Trial for Tenosynovial Giant Cell Tumor

6 months ago

• Pimicotinib (ABSK021) significantly improved the objective response rate (ORR) in patients with tenosynovial giant cell tumor (TGCT) compared to placebo in the phase 3 MANEUVER trial. • The ORR at week 25 was 54.0% for pimicotinib versus 3.2% for placebo (P < .0001), meeting the primary endpoint of the study. • Secondary endpoints, including stiffness and pain reduction, also showed statistically significant and clinically meaningful improvements with pimicotinib treatment. • Pimicotinib was well-tolerated, with a safety profile consistent with prior data, suggesting it could become a new treatment option for TGCT.

Pimicotinib Shows Significant Improvement in Tenosynovial Giant Cell Tumor Treatment

6 months ago

• Phase III MANEUVER study reveals pimicotinib significantly improves outcomes in patients with tenosynovial giant cell tumor (TGCT). • Pimicotinib demonstrates statistically significant improvements in stiffness and pain, key secondary endpoints in the MANEUVER trial. • The oral CSF-1R inhibitor shows a well-tolerated safety profile, with low rates of treatment discontinuation in the study. • Abbisko Therapeutics and Merck KGaA are collaborating to pursue registration of pimicotinib for TGCT treatment in China.